Paper Details

  1. Home
  2. Paper Details

[Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia].

Author: ChaoZhi, ChenXiao-Mei, DUXin, DengCheng-Xin, HuangXin, LaiPei-Long, LiMin-Ming, LiaoPeng-Jun, LingWei, LuZe-Sheng, WanChang-Chun, WangYu-Lian, WengJian-Yu, WuSui-Jing, ZhongLi-Ye, ZouXiao-Li

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The CLAT protocol (cladribine, cytarabine, and topotecan) achieved a 66.7% response rate in patients with refractory acute myeloid leukemia, with a median overall survival time of 9.5 months.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To explore the clinical efficacy and toxicity of CLAT protocol (cladribine, cytarabine and topotecan) for treating patients with refractory acute myeloid leukemia (R-AML). METHODS: A total of 18 patients with R-AML (median age 37 years, range 18 to 58 years; male n = 16, female n = 2) we...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7534/j.issn.1009-2137.2016.02.017

データ提供：米国国立医学図書館（NLM）

CLAT Protocol for Refractory Acute Myeloid Leukemia: A New Oasis in the Desert of Treatment

Acute myeloid leukemia (AML) is a challenging cancer, often requiring aggressive treatments. This study investigates the effectiveness of a new treatment protocol called CLAT for patients with refractory AML, offering a potential oasis in the desert of treatment options.

Promising Results for Refractory AML: The CLAT Protocol

The study found that the CLAT protocol, a combination of drugs, achieved a significant response rate in patients with refractory AML. A significant portion of patients achieved complete remission, demonstrating the potential of this protocol to significantly improve treatment outcomes. The study also highlights the importance of personalized treatment approaches, tailoring therapies to the specific needs of each patient.

Navigating the Desert of Treatment: Finding Hope for Refractory AML

The journey of a cancer patient can be arduous and uncertain, like navigating a vast and unforgiving desert. This study provides a glimmer of hope, highlighting the potential of the CLAT protocol to offer a new treatment avenue for patients with refractory AML. It reminds us that even in the most challenging medical situations, research and innovation can lead to breakthroughs, providing oases of hope and healing for those in need.

Dr.Camel's Conclusion

This research suggests that the CLAT protocol holds promise for treating refractory AML, offering a potential lifeline for patients who have exhausted other treatment options. It underscores the ongoing efforts in cancer research to develop more effective and targeted therapies, providing hope and new possibilities for those facing the daunting challenge of this disease.
Date :
  1. Date Completed 2016-09-15
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27150999

DOI: Digital Object Identifier

10.7534/j.issn.1009-2137.2016.02.017

SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.